Siglec-2/CD22 Antibody (hL22 (Epratuzumab)) - Azide and BSA Free

• Reactivity: Hu, Pm-Cm, RM
• Applications: Flow, IP, B/N
• Clone: hL22 (Epratuzumab)
• Clonality: Monoclonal
• Host: Human
• Conjugate: Unconjugated
• Format: Azide and BSA Free
• Concentration: 1 mg/ml

Siglec-2/CD22 Antibody (hL22 (Epratuzumab)) - Azide and BSA Free Summary

• Immunogen: This antibody was prepared by the humanization of LL2 (EPB-2), a murine anti-CD22 IgG2a raised against Raji Burkitt lymphoma cells. Murine sequences comprise 5-10% of the molecule, with the remainder being human framework sequences, which greatly reduces the potential for immunogenicity (Traczewski, 2010).
• Specificity: This antibody is specific for the 3rd Ig-like domain of human CD22 (epitope B), a cell surface glycoprotein present on mature B-cells and on many types of malignant B-cells.
• Isotype: IgG1 Kappa
• Clonality: Monoclonal
• Host: Human
• Gene: CD22
• Purity: Protein A purified

Applications/Dilutions

• Dilutions:
  • Block/Neutralize
  • Flow Cytometry 1:10 - 1:1000
  • Immunoprecipitation 1:10 - 1:500
• Application Notes: Epratuzumab binds to the third extracellular domain of CD22, inducing CD22 phosphorylation, resulting in negative modulation of BCR activation, and rapid CD22 internalization, leading to modulation of B-cell homing (Traczewski, 2010). Initial phase II and two terminated early phase III studies suggest that the use of this antibody to treat systemic lupus erythematosus is effective and well tolerated, but both phase III trials failed to meet primary clinical efficacy endpoints. Additionally, in vitro studies and clinical trials indicate that this antibody can be used in combination therapy with another inhibitor of B-cell activity, rituximab (anti-CD20), in the treatment of non-Hodgkin lymphoma (Traczewski, 2010).

Packaging, Storage & Formulations

• Storage: Store at 4C for up to 3 months. For longer storage, aliquot and store at -20C.
• Buffer: PBS
• Preservative: 0.02% Proclin 300
• Concentration: 1 mg/ml
• Purity: Protein A purified

Alternate Names for Siglec-2/CD22 Antibody (hL22 (Epratuzumab)) - Azide and BSA Free

• B-cell receptor CD22
• BL-CAM
• B-lymphocyte cell adhesion molecule
• CD22 antigenMGC130020
• CD22 molecule
• CD22
• sialic acid binding Ig-like lectin 2
• Sialic acid-binding Ig-like lectin 2
• Siglec2
• Siglec-2
• SIGLEC2FLJ22814
• T-cell surface antigen Leu-14

Background

CD22 is a single-pass type 1 membrane glycoprotein found in the cytoplasm and cell membrane of B-lymphocytes. CD22 has at least two isoforms (alpha and beta) produced by alternate splicing. The protein exists predominantly as a monomer of the beta isoform (95 kDa). It is also found as a heterodimer of the beta and alpha isoforms.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

FAQs for Siglec-2/CD22 Antibody (NBP2-75188). (Showing 1 - 1 of 1 FAQ).

1. I am interested in buying a CD22 antibody for fluorescence microscopy and FACS I red on your web page that you also offer to label your antibodies, if required, is that correct?  ..show answer..
   • We do have the ability to perform custom conjugations on certain antibodies, including some to the CD22 protein. If you send me the conjugate you are interested in I can provide you with a quote.

Bioinformatics

• Gene Symbol: CD22